InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,702.55
(
-0.19%
)
US TECH 100
19,288.00
(
-0.24%
)
Dow Jones
42,063.36
(
0.09%
)
Brent Oil
74.14
(
-0.25%
)
Bitcoin
63,126.00
(
0.28%
)
Post# of 658767
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

rayank

Send PM Follow Ignore
Followers 74
Posts 10294
Boards Moderated 1
Alias Born 11/22/2004

rayank

Re: None

Tuesday, 07/22/2014 10:41:21 AM

Tuesday, July 22, 2014 10:41:21 AM

Post# of 658767
SNTA: "Synta Pharmaceuticals data positive, says JMP Securities
JMP Securities believes that early top-line data indicates Synta's ganetespib plus current standard of care, low-dose Ara-C provide clinical benefit in high-risk elderly patients with newly diagnosed AML and MDS. The firm says the results increase its confidence in a positive GALAXY-2 outcome in NSCLC and broad applicability of ganetespib across a variety of tumor types. It keeps an Outperform rating on the stock".
http://www.theflyonthewall.com/permalinks/entry.php/SNTAid2041209/SNTA-Synta-Pharmaceuticals-data-positive--says-JMP-Securities

Rayank

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up